Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
0.135(c) 0.135(c) 0.13(c) 0.125(c) 0.13 Last
375 500 39 920 53 950 163 678 34 505 Volume
+8.00% 0.00% -3.70% -3.85% +4.00% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -6,80 M -5,16 M -5,16 M
Net Debt 2020 - - -
P/E ratio 2020 -6,33x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -15,6 M -11,8 M -11,8 M
Net Debt 2021 - - -
P/E ratio 2021 -3,17x
Yield 2021 -
Capitalization 36,2 M 27,6 M 27,5 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees -
Free-Float 90,1%
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and... 
More about the company
All news about PROMIS NEUROSCIENCES, INC.
10/21PROMIS NEUROSCIENCES' PERSPECTIVE ON : is approval likely?
PU
10/21PROMIS NEUROSCIENCES : Offers its Perspective on the Likelihood of Regulatory Ap..
AQ
10/21PROMIS NEUROSCIENCES : Offers its Perspective on the Likelihood of Regulatory Ap..
AQ
10/21ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory A..
GL
10/14PROMIS NEUROSCIENCES : Neil Cashman to Speak at Protein Misfolding Drug Discover..
AQ
10/13PROMIS NEUROSCIENCES : rsquo; Neil Cashman to Speak at Protein Misfolding Drug D..
AQ
10/13PROMIS NEUROSCIENCES : rsquo; Neil Cashman to Speak at Protein Misfolding Drug D..
AQ
10/13ProMIS Neurosciences' Neil Cashman to Speak at Protein Misfolding Drug Disco..
GL
09/23PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
PU
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22PROMIS NEUROSCIENCES : to develop multivalent vaccine for Alzheimer's disease
AQ
09/22ProMIS Neurosciences to develop multivalent vaccine for Alzheimer's disease
GL
09/10PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 22nd Annual Inves..
AQ
09/10PROMIS NEUROSCIENCES : to Participate in H.C. Wainwright & Co. 22nd Annual Inves..
AQ
More news
News in other languages on PROMIS NEUROSCIENCES, INC.

- No features available -

More news
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 4,16 $
Last Close Price 0,09 $
Spread / Highest target 4 281%
Spread / Average Target 4 281%
Spread / Lowest Target 4 281%
EPS Revisions
Managers
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.-23.53%28
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.60%39 515
BEIGENE, LTD.82.54%27 421